Most Recent Articles by Noah Pines
A relative's illness challenges a pharma consultant's view of industry progress.
With some of the biggest patent expiries due to pass in 2013, the next two years will be important in terms of pharma's return to growth, says Sanford Bernstein's Dr. Tim Anderson in a discussion with Noah Pines
Abbott and BMS peeled back the curtain on some impressive clinical trial results, suggesting that Gilead may have some competition in the sprint for an all-oral anti-HCV treatment.
The deadly meningitis outbreak highlights the threat not only to public health, but also to the pharma industry, posed by the largely unregulated practice of pharmacy compounding.
Boehringer Ingelheim has long been associated with treatments for stroke prevention, COPD and HIV/AIDS, but not cancer. That's about to change, if a cornucopia of 13 abstracts presented at the European Society for Medical Oncology (ESMO) is any evidence.
More Articles by Noah Pines
What does going "beyond the pill" actually mean? At MM&M's recent inaugural spring conference, audience members heard from real-world companies that are managing the organizational, technological, and promotional challenges inherent in this transition, such as partnering with health neophytes, harnessing technologies that allow deeper engagement with patients, and adopting a new commercial mindset to serve, not sell. Download here.
A wave of more effective anti-cancer drugs has set the oncology world on fire with enthusiasm. While many hail this as a new era, an equally vocal faction questions the money spent for the value gained. This medical and commercial trend report for marketers of anti-cancer modalities touches on many of the latest shifts that have expedited product launches and otherwise impacted promotion and reimbursement of these drugs. Click here.